About This Seminar
This webinar will explore the feasibility of conducting a phase III vaccine trial for a CCHFV-specific vaccine. Through mathematical models, we will estimate key trial design components such as sample size and time to attain the necessary number of trial endpoints in three different endemic settings: Afghanistan, South Africa, and Turkey.
Crimean-Congo Haemorrhagic Fever (CCHF) virus (CCHFV) is a zoonotic tick-borne emerging pathogen that can lead to fatal haemorrhagic fever in humans. Despite this, no effective vaccine formulation is currently available, while the epidemiological map of influence for CCHFV keeps expanding.
Key Topics
Feasibility of conducting phase III vaccine trials for CCHFV
Mathematical modeling for trial design
Sample size estimation for vaccine trials
Time to endpoint analysis
Comparative analysis across endemic settings
Study Settings
Seminar Details
Dr. Juan Vesga is a Lead Infectious Disease and Vaccine Modeller at the UK Health Security Agency and a visiting researcher at Imperial College London. His work focuses on using mathematical models to understand disease dynamics of preventable diseases and the impact of interventions. His research on CCHF was developed during his time at the London School of Hygiene and Tropical Medicine, where he also developed models for tick-borne diseases like Lyme Disease and Tick-borne Encephalitis.
